UEGweek 2025

A new oral α4β7 integrin inhibitor - more questions…

New rumours about small molecules

IL-23 inhibition: sc is nice, oral is better ?!

AI AI captain! - AI improves histological diagnostics

Fistulizing perianal disease - still challenging!

Are JAK inhibitors better than their reputation?

If it helps, can we stop it? Drug withdrawel in IBD

A new oral inhibitor is changing the IL-23 landscape?

Timing is everything - surgical intervention in CD

Modifying the diet does have an impact on IBD risk!

Finally time to stop the automatic continuation of…

Efficacy of sc induction with guselkumab therapy in UC

Do biologics need an iv induction?

T2T in UC - first piece of restrospective evidence

Braucht es eine i.v. Induktion bei Biologika?

Effektivität der s.c. Induktion mit Guselkumab bei UC

Endlich Zeit das automatisierte 5-ASA Weiterführen zu…

Efficacy of Guselkumab in CD patients who lost response…

To stop or not to stop? That is the question (in…

Is it possible to stop anti-TNF treatment in early CD…

Injecting in fistulas: the never ending story?

Early treatment with adalimumab does not allow for…

10 years after the LIR!C trial – the update of the…

Efficacy of guselkumab in patients with inadequate…

Perianal CD - it's associated with low infliximab…

Therapy sequence: guselkumab is possible after…

Can we stop Adalimumab in CD patients achieving…

Czy przerywać skuteczne leczenie u pacjentów z chorobą…

Peut-on arrêter un anti-TNF dans la maladie de Crohn…

10 lat po badaniu LIR!C – aktualizacja danych o…

הזרקת תאים לפיסטולה במחלת קרוהן- הסיפור שאינו נגמר?

Possiamo sospendere Adalimumab in pazienti affetti da…

Ασθενείς με πρόσφατη έναρξη νόσου του Crohn σε…

Therapiesequenz: Guselkumab nach Ustekinumab-Versagen…

Oral mufemilast, a PDE4 inhibitor, for moderate to…

Icotrokina - a new oral drug for blocking IL-23

Obefazimod - a new mechanism of action for the…

IL-23 blockade now also oral

B-cell depletion in refractory ulcerative colitis –…

Go for oral anti-α4β7!

Mufemilast, αναστολέας της PDE4, για θεραπεία από του…

Puntare sugli anti-α4β7 orali!

Obefazimod - Une nouvelle classe thérapeutique pour la…

B-Zell-Depletion bei refraktärer Colitis Ulcerosa -…

IL-23 Blockade jetzt auch oral

Obefazimod in moderate to severe UC

Short-term (8 weeks) efficacy & safety of obefazimod in…

Histo-endoscopic endpoint in long-term extension of…

Real-world short-term efficacy and safety of…

Long term persistence of ustekinumab in Real-Life…

Etrasimod in mild to moderate UC

Obefazimod nella colite ulcerosa da moderata a grave

Eficacia y seguridad a corto plazo (8 semanas) de…

Etrasimod nella colite ulcerosa da lieve a moderata

Μακροχρόνια αποτελεσματικότητα της ουστεκινουμάμπης σε…

JAK-Inhibitoren sind vielleicht sicherer als Sie…

Endlich Zeit das automatisierte 5-ASA Weiterführen zu…

Obefazimod-Induktionstherapie ist effektiv und gut…

Risankizumab in Crohn’s disease - real-world data…

Ustekinumab in perianal Crohn’s disease

Dane typu real-life a badania kliniczne risankizumabu w…

Guselkumab sc en enfermedad de crohn con respuesta…

AI-endoscopy ready - is it a game changer?

IUS as a patient- and environmental-friendly tool in…

Real-life vs clinical trials IBD patients access to…

Reassuring safety signals of JAKis in pregnant IBD…

Eosinophilic esophagitis doesn’t seem to increase the…

Sigmoid volvulus: an old problem, still waiting for…

New insights from the GEM trail

When nanoparticles calm down celiac-specific T-cells

IBD outcome in a large national cohort from spain

Selection criteria for randomized clinical trials in…

JAKis and pregnany in IBD

Steroid-sparing effect of upfront Vedolizumab in…

Looking for the black sheep pathways

Let's go green! ecological effect of patient monitoring

Co ma wspólnego USG jelit w IBD z ekologią?

Auf der Suche nach den schwarzen Pathway-Schafen

Vedolizumab - eine zusätzliche Therapieoption bei…

Verso il verde! L’impatto ecologico del monitoraggio…

JAK-Inhibitoren und Schwangerschaft bei CED

Segnali si sicurezza rassicuranti in donne affette da…

Πρόσβαση σε προχωρημένες θεραπείες καθημερινών ασθενών…

Critères de sélection des essais cliniques randomisés…

Wenn Nanopartikel zöliakiespezifische T-Zellen…

Risparmio di steroidi in pazienti con colite indotta da…

פתלת הפרשדון....בעיה מוכרת שעדין מחכה לפתרון